DK2074122T5 - Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer - Google Patents

Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer Download PDF

Info

Publication number
DK2074122T5
DK2074122T5 DK07804890.7T DK07804890T DK2074122T5 DK 2074122 T5 DK2074122 T5 DK 2074122T5 DK 07804890 T DK07804890 T DK 07804890T DK 2074122 T5 DK2074122 T5 DK 2074122T5
Authority
DK
Denmark
Prior art keywords
pyrimidinon
pyrido
inhibitors
compounds
pyrimidinon compounds
Prior art date
Application number
DK07804890.7T
Other languages
English (en)
Other versions
DK2074122T3 (da
Inventor
Hengmiao Cheng
Dilip Bhumralkar
Klaus Ruprecht Dress
Jacqui Elizabet Hoffman
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mason Alan Pairish
Michael Bruno Plewe
Khanh Tuan Tran
Mitchell David Nambu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK2074122T3 publication Critical patent/DK2074122T3/da
Publication of DK2074122T5 publication Critical patent/DK2074122T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
DK07804890.7T 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer DK2074122T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
DK2074122T3 DK2074122T3 (da) 2011-08-15
DK2074122T5 true DK2074122T5 (da) 2014-03-17

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07804890.7T DK2074122T5 (da) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer

Country Status (42)

Country Link
US (3) US7696213B2 (da)
EP (1) EP2074122B9 (da)
JP (1) JP4718637B2 (da)
KR (1) KR101099926B1 (da)
CN (1) CN101573358B (da)
AP (1) AP2710A (da)
AR (1) AR062785A1 (da)
AT (1) ATE514695T1 (da)
AU (1) AU2007297212B8 (da)
BR (1) BRPI0716749B8 (da)
CA (1) CA2663401C (da)
CL (1) CL2007002682A1 (da)
CR (1) CR10662A (da)
CU (1) CU23783B7 (da)
CY (1) CY1111911T1 (da)
DK (1) DK2074122T5 (da)
DO (1) DOP2009000039A (da)
EA (1) EA016388B1 (da)
ES (1) ES2366489T3 (da)
GE (1) GEP20115306B (da)
GT (1) GT200700077A (da)
HK (1) HK1138589A1 (da)
HN (1) HN2007000267A (da)
HR (1) HRP20110621T2 (da)
IL (1) IL197243A (da)
MA (1) MA30709B1 (da)
ME (1) MEP8009A (da)
MX (1) MX2009002927A (da)
MY (1) MY146420A (da)
NI (1) NI200900032A (da)
NO (1) NO342357B1 (da)
NZ (1) NZ575167A (da)
PE (1) PE20080670A1 (da)
PL (1) PL2074122T3 (da)
PT (1) PT2074122E (da)
RS (2) RS20090104A (da)
SI (1) SI2074122T1 (da)
TN (1) TN2009000085A1 (da)
TW (1) TWI334353B (da)
UY (1) UY30588A1 (da)
WO (1) WO2008032162A1 (da)
ZA (1) ZA200901477B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE514695T1 (de) 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
CN102727498B (zh) * 2007-04-10 2016-08-03 埃克塞里艾克西斯公司 使用吡啶并嘧啶酮PI3Kα抑制剂的治疗方法
KR20090130104A (ko) * 2007-04-11 2009-12-17 엑셀리시스, 인코포레이티드 암 치료를 위한 ｐｉ３ｋ－알파의 억제제로서의 피리도〔２，３­ｄ〕피리미딘­７­온 화합물
MX2011000440A (es) * 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5619743B2 (ja) * 2008-08-20 2014-11-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
AU2009282572B2 (en) 2008-08-20 2014-09-11 Merck Sharp & Dohme Corp. Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY32153A (es) * 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
PT2651951E (pt) 2010-12-16 2015-01-14 Hoffmann La Roche Compostos tricíclicos do inibidor pi3k e processos para a sua utilização
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX2014002471A (es) 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
KR20170058432A (ko) 2014-10-10 2017-05-26 화이자 인코포레이티드 상승 효과적 아우리스타틴 조합
BR112017025398A2 (pt) 2015-06-04 2018-08-07 Pfizer Inc. formas de dosagem sólidas de palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US10919877B2 (en) 2016-07-06 2021-02-16 The Regents Of The University Of Michigan Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
SI3497103T1 (sl) 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6
CA3045041A1 (en) * 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
RS65761B1 (sr) 2018-06-15 2024-08-30 Janssen Pharmaceutica Nv Analozi rapamicina i njihova upotreba
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
CA3238551A1 (en) * 2021-11-18 2023-05-25 Steven FRUCHTMAN Methods and compositions for treating cancer

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
PL181893B1 (pl) 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
IL150742A0 (en) 2000-01-27 2003-02-12 Warner Lambert Co Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
SK12472002A3 (sk) 2000-03-06 2003-04-01 Warner-Lambert Company 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz
CA2407593C (en) 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
AU2002233706C1 (en) 2001-02-26 2005-12-22 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
CA2482022A1 (en) 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
BR0309581A (pt) 2002-05-06 2005-03-29 Genelabs Tech Inc Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
AU2005214352B2 (en) 2004-02-14 2009-11-12 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0507852A (pt) 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
JP2007530654A (ja) 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
WO2005117980A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
PL1940839T3 (pl) * 2005-10-07 2013-12-31 Exelixis Inc Pirydopirymidynonowe inhibitory PI3Kalfa
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
EP2056829B9 (en) 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ATE514695T1 (de) 2006-09-15 2011-07-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren
WO2008112913A1 (en) * 2007-03-14 2008-09-18 Exelixis, Inc. Inhibitors of the hedgehog pathway
KR20090130104A (ko) 2007-04-11 2009-12-17 엑셀리시스, 인코포레이티드 암 치료를 위한 ｐｉ３ｋ－알파의 억제제로서의 피리도〔２，３­ｄ〕피리미딘­７­온 화합물
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
EA200970207A1 (ru) 2009-08-28
US20080090801A1 (en) 2008-04-17
ZA200901477B (en) 2010-07-28
RS51927B (en) 2012-02-29
BRPI0716749B1 (pt) 2020-10-06
HRP20110621T1 (en) 2011-09-30
CL2007002682A1 (es) 2008-04-04
TN2009000085A1 (fr) 2010-08-19
NZ575167A (en) 2010-10-29
EP2074122B1 (en) 2011-06-29
US20100137279A1 (en) 2010-06-03
MEP8009A (en) 2011-12-20
NO342357B1 (no) 2018-05-14
CA2663401A1 (en) 2008-03-20
CU20090040A7 (es) 2011-07-11
WO2008032162A8 (en) 2009-03-26
US8633204B2 (en) 2014-01-21
US7696213B2 (en) 2010-04-13
EA016388B1 (ru) 2012-04-30
NI200900032A (es) 2010-05-14
CR10662A (es) 2009-04-17
IL197243A0 (en) 2009-12-24
IL197243A (en) 2013-07-31
WO2008032162A1 (en) 2008-03-20
BRPI0716749A2 (pt) 2014-02-18
JP4718637B2 (ja) 2011-07-06
TWI334353B (en) 2010-12-11
PE20080670A1 (es) 2008-06-14
EP2074122B9 (en) 2013-09-11
US8273755B2 (en) 2012-09-25
AU2007297212B2 (en) 2011-04-14
KR101099926B1 (ko) 2011-12-28
GT200700077A (es) 2009-08-03
MA30709B1 (fr) 2009-09-01
EP2074122A1 (en) 2009-07-01
PL2074122T3 (pl) 2011-10-31
HRP20110621T2 (hr) 2013-12-06
RS20090104A (en) 2010-06-30
AP2009004790A0 (en) 2009-04-30
UY30588A1 (es) 2008-05-02
MY146420A (en) 2012-08-15
AR062785A1 (es) 2008-12-03
HN2007000267A (es) 2011-02-25
DOP2009000039A (es) 2015-12-15
CU23783B7 (es) 2012-02-15
CY1111911T1 (el) 2015-11-04
TW200820972A (en) 2008-05-16
SI2074122T1 (sl) 2011-10-28
AP2710A (en) 2013-07-30
CN101573358A (zh) 2009-11-04
AU2007297212A1 (en) 2008-03-20
PT2074122E (pt) 2011-08-24
ES2366489T3 (es) 2011-10-20
HK1138589A1 (en) 2010-08-27
CN101573358B (zh) 2012-05-30
DK2074122T3 (da) 2011-08-15
JP2010503653A (ja) 2010-02-04
KR20090040389A (ko) 2009-04-23
NO20091141L (no) 2009-03-31
ES2366489T9 (es) 2013-12-27
BRPI0716749B8 (pt) 2021-05-25
CA2663401C (en) 2011-07-12
GEP20115306B (da) 2011-10-10
ATE514695T1 (de) 2011-07-15
MX2009002927A (es) 2009-03-31
US20120309775A1 (en) 2012-12-06
AU2007297212B8 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK2049557T3 (da) 1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
DK1845978T3 (da) Substituerede pyrazolopyridiner, sammensætninger, som indeholder disse, fremgangsmåde til fremstilling heraf, og anvendelse heraf
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2102205T3 (da) Pyridopyrazinderivater anvendelige som herbicidale forbindelser
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK1996557T3 (da) Pyridazinon-forbindelse og anvendelse deraf som herbicid
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
ATE415400T1 (de) Pyrazolopyridinderivate
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2160389T3 (da) Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer